Lab Work for Blood Related Disord: 28.6% of denials overturned
In 21 California IMR decisions from 2006 to 2024, reviewers overturned 6 (28.6%). In the last five years: 0.0% of 3. 4 were medical-necessity disputes, 17 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2022 | 1 | 0.0% |
| 2024 | 2 | 0.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 7 | 14.3% | 28.6% |
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 7 | 14.3% | 28.6% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for targeted genomic sequence analysis panel (CPT 81450) provided by Neogenomics Laboratories. Based on the available documentation, this patient is suspected of having myelodysplastic syndrome (MDS). The National Comprehensive Cancer Network (NCCN) guidelines recommend that bone marrow or peripheral blood cells be assayed for MDS-associated gene mutations using gene panels. …”
“Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for Factor V Leiden mutation testing (CPT 81241). Although no DVT was identified on duplex imaging, the patient did have an episode of superficial venous thrombosis (SVT). In response to this, the work-up was appropriate, given the patient’s age and non-smoker status. Subsequent genetic testing was recommended to determine whether …”
“Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for gene panel testing. The Health Plan has denied this request indicating that the services at issue were considered investigational for evaluation of the enrollee with a history of aplastic anemia.Findings: Prior to transplantation, it is standard practice to check for telomere length for the diagnosis of dyskeratosis congenita (DKC). …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for lab work. Microscopic hematuria may be a sign of urothelial cancer, though gross hematuria has a much higher correlation. Per American Urological Association (AUA) guidelines, `For patients with a prior negative hematuria evaluation who have persistent or recurrent microhematuria at the time of repeat …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Lab Work denials for Blood Related Disord overturned?
In 21 California IMR decisions from 2006 to 2024, reviewers overturned 6 (28.6%). In the last five years: 0.0% of 3. 4 were medical-necessity disputes, 17 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.